Terms: = Leukemia AND TSC2, FLJ43106, 7249, ENSG00000103197, LAM, tuberin, TSC4
91 results:
1. A case of pancreatic PEComa with prominent inflammatory cell infiltration: the inflammatory subtype is a distinct histologic group of PEComa.
Tsukita H; Koyama K; Ishinari T; Takahashi A; Miyabe K; Umakoshi M; Yoshida M; Kudo-Asabe Y; Nishida A; Otsuka N; Yasui O; Kato I; Fukushima N; Goto A
Diagn Pathol; 2024 Apr; 19(1):59. PubMed ID: 38622713
[TBL] [Abstract] [Full Text] [Related]
2. Tri-ing to decipher trisomy AML.
Shimony S; Chen EC
Br J Haematol; 2024 Mar; 204(3):751-752. PubMed ID: 38190804
[TBL] [Abstract] [Full Text] [Related]
3. Clinical and Laboratory Characteristics of IgM Primary Plasma Cell leukemia.
Wu Y; Zhang X; Ma X; Suo X; Li R
Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436385
[TBL] [Abstract] [Full Text] [Related]
4. [Periplaneta americana extract CⅡ-3 induces senescence of leukemia K562 cells via SIRT1/mTOR signaling pathway].
He SY; Zhang CG; Liu H; Zhou Y; Tang ZY; Bi ZY; Tian L; Li MR
Zhongguo Zhong Yao Za Zhi; 2023 Jun; 48(11):3039-3045. PubMed ID: 37381962
[TBL] [Abstract] [Full Text] [Related]
5. l-Asparaginase regulates mTORC1 activity via a tsc2-dependent pathway in pancreatic beta cells.
Seike M; Asahara SI; Inoue H; Kudo M; Kanno A; Yokoi A; Suzuki H; Kimura-Koyanagi M; Kido Y; Ogawa W
Biochem Biophys Res Commun; 2023 Apr; 652():121-130. PubMed ID: 36842323
[TBL] [Abstract] [Full Text] [Related]
6. Knockdown of let-7b in leukemia associated macrophages inhibit acute myeloid leukemia progression.
Tian C; Li Y; Si J; Kang J; Chen Z; Nuermaimaiti R; Wang Y; Yu Y; Zhao Z; Wang X; Zhang Y; Zhao H; Yang H; You MJ; Zheng G; Wang L
Hematol Oncol; 2023 Aug; 41(3):510-519. PubMed ID: 36579468
[TBL] [Abstract] [Full Text] [Related]
7. Renal phenotypes correlate with genotypes in unrelated individuals with tuberous sclerosis complex in China.
Luo C; Zhang Y; Zhang YS; Zhang MX; Ning J; Chen MF; Li Y; Qi L; Zu XB; Li YL; Cai Y
Orphanet J Rare Dis; 2022 Jul; 17(1):288. PubMed ID: 35870981
[TBL] [Abstract] [Full Text] [Related]
8. Establishing and characterizing a novel doxorubicin-resistant acute myeloid leukaemia cell line.
Castro I; Lopes-Rodrigues V; Branco H; Vasconcelos MH; Xavier CPR
J Chemother; 2023 Jul; 35(4):307-321. PubMed ID: 35822500
[TBL] [Abstract] [Full Text] [Related]
9. Tuberous sclerosis complex: a complex case.
Powell RM; Pattison S; Moravec JC; Bhat B; Guirguis N; Markie D; Jones GT; Copedo J; Print CG; Morison IM; Gavryushkin A; Gray B; Wyeth LJ; Eccles MR; Macaulay EC
Cold Spring Harb Mol Case Stud; 2022 Apr; 8(3):. PubMed ID: 35483879
[TBL] [Abstract] [Full Text] [Related]
10. Kidney Transplantation in a Patient With Tuberous Sclerosis Complex: A Case Report.
Kluz A; Gozdowska J; Domagała P; Durlik M
Transplant Proc; 2022 May; 54(4):1148-1151. PubMed ID: 35430095
[TBL] [Abstract] [Full Text] [Related]
11. Molecular characterization of hepatitis B virus (HBV) isolated from a pediatric case of acute lymphoid leukemia, with a delayed response to antiviral treatment: a case report.
Chen CY; Hajinicolaou C; Walabh P; Ingasia LAO; Song E; Kramvis A
BMC Pediatr; 2022 Mar; 22(1):168. PubMed ID: 35361141
[TBL] [Abstract] [Full Text] [Related]
12. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract] [Full Text] [Related]
13. Sporadic facial angiofibroma and sporadic angiomyolipoma mimicking tuberous sclerosis complex.
Klonowska K; Thiele EA; Grevelink JM; Thorner AR; Kwiatkowski DJ
J Med Genet; 2022 Sep; 59(9):920-923. PubMed ID: 34635572
[TBL] [Abstract] [Full Text] [Related]
14. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
[TBL] [Abstract] [Full Text] [Related]
15. Prognosis and Characterization of Immune Microenvironment in Acute Myeloid leukemia Through Identification of an Autophagy-Related Signature.
Fu D; Zhang B; Wu S; Zhang Y; Xie J; Ning W; Jiang H
Front Immunol; 2021; 12():695865. PubMed ID: 34135913
[TBL] [Abstract] [Full Text] [Related]
16. Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Damnernsawad A; Bottomly D; Kurtz SE; Eide CA; McWeeney SK; Tyner JW; Nechiporuk T
Haematologica; 2022 Jan; 107(1):77-85. PubMed ID: 33375770
[TBL] [Abstract] [Full Text] [Related]
17. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract] [Full Text] [Related]
18. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Largeaud L; Cornillet-Lefebvre P; Hamel JF; Dumas PY; Prade N; Dufrechou S; Plenecassagnes J; Luquet I; Blanchet O; Banos A; Béné MC; Bernard M; Bertoli S; Bonmati C; Fornecker LM; Guièze R; Haddaoui L; Hunault M; Ianotto JC; Jourdan E; Ojeda M; Peterlin P; Vey N; Zerazhi H; Yosr H; Mineur A; Cahn JY; Ifrah N; Récher C; Pigneux A; Delabesse E;
Leukemia; 2021 May; 35(5):1291-1300. PubMed ID: 32943750
[TBL] [Abstract] [Full Text] [Related]
19. Ginsenoside Rg1 Inhibits Cell Proliferation and Induces Markers of Cell Senescence in CD34+CD38- leukemia Stem Cells Derived from KG1α Acute Myeloid leukemia Cells by Activating the Sirtuin 1 (SIRT1)/Tuberous Sclerosis Complex 2 (tsc2) Signaling Pathway.
Tang YL; Zhang CG; Liu H; Zhou Y; Wang YP; Li Y; Han YJ; Wang CL
Med Sci Monit; 2020 Feb; 26():e918207. PubMed ID: 32037392
[TBL] [Abstract] [Full Text] [Related]
20. lam-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
[TBL] [Abstract] [Full Text] [Related]
[Next]
